LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 331

Search options

  1. Article ; Online: Too many antibiotics for patients with COVID-19 despite low bacterial infections.

    Giacobbe, Daniele Roberto / Bassetti, Matteo

    The Lancet. Infectious diseases

    2023  Volume 23, Issue 6, Page(s) 636–637

    MeSH term(s) Humans ; COVID-19/microbiology ; Anti-Bacterial Agents/therapeutic use ; Bacterial Infections/drug therapy ; Bacterial Infections/microbiology ; SARS-CoV-2
    Chemical Substances Anti-Bacterial Agents
    Language English
    Publishing date 2023-01-27
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 2061641-7
    ISSN 1474-4457 ; 1473-3099
    ISSN (online) 1474-4457
    ISSN 1473-3099
    DOI 10.1016/S1473-3099(22)00866-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Response to: "the impact of age, disease severity, and vaccination status on antibiotic use in hospitalized patients with COVID-19".

    Bassetti, Matteo / Brucci, Giorgia / Vena, Antonio / Giacobbe, Daniele Roberto

    Expert opinion on pharmacotherapy

    2024  Volume 24, Issue 18, Page(s) 2229–2230

    MeSH term(s) Humans ; COVID-19 ; Patient Acuity ; Vaccination ; Anti-Bacterial Agents/therapeutic use
    Chemical Substances Anti-Bacterial Agents
    Language English
    Publishing date 2024-01-05
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 2001535-5
    ISSN 1744-7666 ; 1465-6566
    ISSN (online) 1744-7666
    ISSN 1465-6566
    DOI 10.1080/14656566.2023.2270419
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Editorial of Special Issue "The COVID-19 Pandemic and Bacterial Infections: Microbiological and Clinical Aspects".

    Di Pilato, Vincenzo / Giacobbe, Daniele Roberto

    Microorganisms

    2023  Volume 11, Issue 4

    Abstract: The emergence in late 2019 of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the pandemic coronavirus disease 2019 (COVID-19), posed significant health challenges worldwide [ ... ]. ...

    Abstract The emergence in late 2019 of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the pandemic coronavirus disease 2019 (COVID-19), posed significant health challenges worldwide [...].
    Language English
    Publishing date 2023-04-12
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2720891-6
    ISSN 2076-2607
    ISSN 2076-2607
    DOI 10.3390/microorganisms11041009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: The safety of ceftolozane/tazobactam for the treatment of complicated urinary tract infections.

    Bassetti, Matteo / Vena, Antonio / Giacobbe, Daniele Roberto

    Expert opinion on drug safety

    2023  Volume 22, Issue 7, Page(s) 533–540

    Abstract: Introduction: Ceftolozane is a cephalosporin similar to ceftazidime in its structure, which is marketed in combination with tazobactam, a well-known β-lactamase inhibitor.: Areas covered: After a brief introduction on the drug characteristics and ... ...

    Abstract Introduction: Ceftolozane is a cephalosporin similar to ceftazidime in its structure, which is marketed in combination with tazobactam, a well-known β-lactamase inhibitor.
    Areas covered: After a brief introduction on the drug characteristics and efficacy, we focused on available data from randomized controlled trials and post-marketing observational studies pertaining to the safety of ceftolozane/tazobactam (C/T) for the treatment of complicated urinary tract infections (cUTI). A search was conducted in PubMed from January 2010 to February 2023.
    Expert opinion: The use of C/T for the treatment of cUTI is supported by solid efficacy and safety data, especially for the treatment of those pathogens where it can represent a first-line approach due to some peculiar characteristics: (i) treatment of cUTI caused by multidrug-resistant
    MeSH term(s) Humans ; Anti-Bacterial Agents/adverse effects ; Tazobactam/adverse effects ; Cephalosporins/adverse effects ; Urinary Tract Infections/drug therapy ; Urinary Tract Infections/chemically induced ; Carbapenems
    Chemical Substances ceftolozane (37A4IES95Q) ; Anti-Bacterial Agents ; ceftolozane, tazobactam drug combination ; Tazobactam (SE10G96M8W) ; Cephalosporins ; Carbapenems
    Language English
    Publishing date 2023-07-03
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2088728-0
    ISSN 1744-764X ; 1474-0338
    ISSN (online) 1744-764X
    ISSN 1474-0338
    DOI 10.1080/14740338.2023.2227085
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Colistin versus colistin plus meropenem for severe infections.

    Giacobbe, Daniele Roberto

    The Lancet. Infectious diseases

    2018  Volume 18, Issue 5, Page(s) 494–495

    MeSH term(s) Carbapenems ; Colistin ; Gram-Negative Bacteria ; Meropenem
    Chemical Substances Carbapenems ; Meropenem (FV9J3JU8B1) ; Colistin (Z67X93HJG1)
    Language English
    Publishing date 2018-05-31
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 2061641-7
    ISSN 1474-4457 ; 1473-3099
    ISSN (online) 1474-4457
    ISSN 1473-3099
    DOI 10.1016/S1473-3099(18)30217-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Management of nonfermenting gram-negative infections: a critique of the guidelines.

    Bassetti, Matteo / Vena, Antonio / Giacobbe, Daniele Roberto

    Current opinion in infectious diseases

    2023  Volume 36, Issue 6, Page(s) 609–614

    Abstract: Purpose of review: In the present narrative review, we discuss the characteristics and differences between the Infectious Diseases Society of America (IDSA) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines in ... ...

    Abstract Purpose of review: In the present narrative review, we discuss the characteristics and differences between the Infectious Diseases Society of America (IDSA) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines in terms on their recommendations/suggestions for the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii infections.
    Recent findings: Treatment of severe infections caused by nonfermenting gram-negative bacteria (NF-GNB) is posing both novel hopes and novel challenges to physicians worldwide, and both the IDSA and the ESCMID have recently updated/released their guidelines or guidance documents, based on different philosophies and providing recommendations for the treatment of NF-GNB infections. In order to correctly exploit recent advances in the treatment of such infections, IDSA and ESCMID approaches should be viewed as complementary and evolving, and should not preclude further revision based on accumulating evidence on the use of novel β-lactams and β-lactam/β-lactamase inhibitor combinations.
    Summary: A joint consideration of both philosophies should leave the door opened for the wise use of novel agents, ultimately building precious experience on their use that could favorably influence future guidelines revisions.
    MeSH term(s) Humans ; Anti-Bacterial Agents/therapeutic use ; Anti-Bacterial Agents/pharmacology ; Gram-Negative Bacteria ; beta-Lactamase Inhibitors/therapeutic use ; beta-Lactams/therapeutic use ; Acinetobacter Infections/drug therapy ; Monobactams/therapeutic use ; Communicable Diseases
    Chemical Substances Anti-Bacterial Agents ; beta-Lactamase Inhibitors ; beta-Lactams ; Monobactams
    Language English
    Publishing date 2023-09-28
    Publishing country United States
    Document type Review ; Journal Article
    ZDB-ID 645085-4
    ISSN 1473-6527 ; 1535-3877 ; 0951-7375 ; 1355-834X
    ISSN (online) 1473-6527 ; 1535-3877
    ISSN 0951-7375 ; 1355-834X
    DOI 10.1097/QCO.0000000000000982
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Clinical interpretation of an interpretable prognostic model for patients with COVID-19

    Giacobbe, Daniele Roberto

    Nature Machine Intelligence ; ISSN 2522-5839

    2020  

    Keywords covid19
    Language English
    Publisher Springer Science and Business Media LLC
    Publishing country us
    Document type Article ; Online
    DOI 10.1038/s42256-020-0207-0
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  8. Article: Reducing dissemination of carbapenem-resistant

    Bassetti, Matteo / Giacobbe, Daniele Roberto

    Annals of translational medicine

    2020  Volume 7, Issue Suppl 8, Page(s) S365

    Language English
    Publishing date 2020-01-03
    Publishing country China
    Document type Editorial ; Comment
    ZDB-ID 2893931-1
    ISSN 2305-5847 ; 2305-5839
    ISSN (online) 2305-5847
    ISSN 2305-5839
    DOI 10.21037/atm.2019.09.11
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: A look at the clinical, economic, and societal impact of antimicrobial resistance in 2020.

    Bassetti, Matteo / Giacobbe, Daniele Roberto

    Expert opinion on pharmacotherapy

    2020  Volume 21, Issue 17, Page(s) 2067–2071

    Keywords covid19
    Language English
    Publishing date 2020-08-04
    Publishing country England
    Document type Editorial
    ZDB-ID 2001535-5
    ISSN 1744-7666 ; 1465-6566
    ISSN (online) 1744-7666
    ISSN 1465-6566
    DOI 10.1080/14656566.2020.1802427
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Emerging treatment options for skin and soft tissue infections tailoring drug selection to individual patients.

    Castaldo, Nadia / Vena, Antonio / Limongelli, Alessandro / Giacobbe, Daniele Roberto / Bassetti, Matteo

    Current opinion in infectious diseases

    2024  Volume 37, Issue 2, Page(s) 80–86

    Abstract: Purpose of review: To provide a brief overview of drugs in Phase II and III of development for the treatment of acute bacterial skin and skin structure infections (ABSSSI), offering insights into potential customized treatment options.: Recent ... ...

    Abstract Purpose of review: To provide a brief overview of drugs in Phase II and III of development for the treatment of acute bacterial skin and skin structure infections (ABSSSI), offering insights into potential customized treatment options.
    Recent findings: Several drugs are currently in advanced stages of evaluation for the treatment of ABSSSI, and numerous molecules are entering in the early development phases. Notably, many of these drugs exhibit unique mechanisms of action and interesting antimicrobial spectrum.
    Summary: Tailoring antibiotic therapy based on patient characteristics, likely pathogens, type, site and severity of ABSSSI is crucial. Given the inherent limitations of available treatments, the development of novel agents is a pivotal avenue. Such advancements hold promise for enhancing treatment efficacy and simplifying drug selection for ABSSSI in everyday clinical practice.
    MeSH term(s) Humans ; Soft Tissue Infections/drug therapy ; Skin Diseases, Bacterial/drug therapy ; Skin Diseases, Bacterial/microbiology ; Anti-Bacterial Agents ; Treatment Outcome
    Chemical Substances Anti-Bacterial Agents
    Language English
    Publishing date 2024-01-24
    Publishing country United States
    Document type Review ; Journal Article
    ZDB-ID 645085-4
    ISSN 1473-6527 ; 1535-3877 ; 0951-7375 ; 1355-834X
    ISSN (online) 1473-6527 ; 1535-3877
    ISSN 0951-7375 ; 1355-834X
    DOI 10.1097/QCO.0000000000001003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top